Table 2.
Prognostic biomarkers identified in the TCGA and our Swedish cohorts.
| Biomarker | Cohort 1 | Rank 2 | Regulation 3 | Prognostic Value 4 |
|---|---|---|---|---|
| ESM1 | All | Top20 | Up | Unfavorable in males |
| CLDN1 | All | Top20 | Up | Unfavorable in females |
| TSPAN7 | Female TCGA | 39 | Down | Unfavorable in females |
| SLC25A23 | Female TCGA | 35 | Down | Unfavorable in females |
| C2orf88 | Female TCGA | 36 | Down | Favorable in males |
| PKIB | Male TCGA | 27 | Down | Favorable in males |
| P2RYI | Male TCGA | 37 | Down | Favorable in females |
| RSPO2 | Male TCGA | 29 | Down | Unfavorable in females |
| GCNT2 | Male TCGA and Swedish | Top20 | Down | Unfavorable in females |
| HPSE2 | TCGA | 35 M and 25 F | Down | Favorable in males |
| GUCA2A | TCGA | 31 M and 44 F | Down | Favorable in males |
| SLC4A4 | TCGA | 23 M and 43 F | Down | Favorable in males |
| KIF26B | Swedish | 6 | Up | Unfavorable in males |
| PTGDR2 | Swedish | 15 | Down | Favorable in males and females (combined) |
| ASPA | Female TCGA | 23 | Down | Unfavorable in males and females (combined) |
| BEST4 | Female TCGA | 17 | Down | Favorable in males and females (combined) |
| NR3C2 | Male TCGA | 30 | Down | Favorable in males and females (combined) |
| SMOX | Male TCGA | 37 | Up | Unfavorable in females |
| FUT1 | All | 38 M, 78 F and 27 S | Up | Unfavorable in females |
| EGFL6 | Female TCGA | 27 | Up | Favorable in females |
| VWA2 | Male TCGA | 31 | Up | Unfavorable in males |
| FJX1 | TCGA | 67 M and 83 F | Up | Unfavorable in males |
| S100A2 | TCGA | 64 M and 45 F | Up | Unfavorable in males |
| EPHX4 | Female TCGA | 75 | Up | Favorable in females |
1 The cohort the biomarker was identified in. 2 The rank of the biomarker after importance ranking with machine learning. 3 Whether the biomarker was up- or downregulated (in the tumor and specified cohort). 4 Whether the biomarker correlated to a favorable or unfavorable prognostic value when highly expressed in males, females, or when both sexes were combined.